Ensemblins (macrocycle IL-17 antagonist program) / Ensemble Therap, BMS, Novartis - LARVOL DELTA

Ensemble therapeutics forms global strategic collaboration for development of oral, macrocyclic IL-17 antagonists and additional disease targets (Ensemble Press Release) - "Ensemble Therapeutics...announced the initiation of a two-part research and development collaboration with Novartis. The companies have entered into a strategic development agreement for Ensemble’s most advanced proprietary program that targets the inflammatory cytokine IL-17, and for a new program to discover novel small molecule treatments against undisclosed drug targets specified by Novartis using Ensemble’s proprietary drug discovery platforms."

Licensing / partnership • Immunology • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis

Ensemble Learning of QTL Models Improves Prediction of Complex Traits. (PubMed) - "TAGGING-assisted QTL mapping substantially improved prediction ability for both biparental and multi-family populations, by reducing both the variance and bias in prediction. Furthermore, an ensemble model combining predictions from TAGGING-assisted QTL and infinitesimal models improved prediction abilities over the component models, indicating some complementarity between model assumptions and suggesting that some trait genetic architectures involve a mixture of a few major QTL and polygenic effects."

Journal • Biosimilar